Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OPK 
Opko Health Inc (OPK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: OPK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.62
1 Year Target Price $3.62
| 2 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.93% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.07B USD | Price to earnings Ratio - | 1Y Target Price 3.62 |
Price to earnings Ratio - | 1Y Target Price 3.62 | ||
Volume (30-day avg) 7 | Beta 1.19 | 52 Weeks Range 1.11 - 2.04 | Updated Date 08/15/2025 |
52 Weeks Range 1.11 - 2.04 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.1133 | Actual -0.19 |
Profitability
Profit Margin -26.68% | Operating Margin (TTM) -38.25% |
Management Effectiveness
Return on Assets (TTM) -8.46% | Return on Equity (TTM) -13.16% |
Valuation
Trailing PE - | Forward PE 64.52 | Enterprise Value 1195628753 | Price to Sales(TTM) 1.61 |
Enterprise Value 1195628753 | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 1.8 | Enterprise Value to EBITDA 20.05 | Shares Outstanding 793782976 | Shares Floating 376110157 |
Shares Outstanding 793782976 | Shares Floating 376110157 | ||
Percent Insiders 46.77 | Percent Institutions 31.96 |
Upturn AI SWOT
Opko Health Inc
Company Overview
History and Background
Opko Health Inc. was founded in 1991. It is a diversified healthcare company that seeks to establish industry-leading positions in diagnostics, pharmaceuticals, and biologics. Over time, it has expanded its product portfolio through acquisitions and internal development.
Core Business Areas
- Diagnostics: Development and commercialization of molecular diagnostics and point-of-care testing platforms.
- Pharmaceuticals: Development and commercialization of pharmaceutical products, including Rayaldee for secondary hyperparathyroidism.
- Biologics: Development of biologic products, including growth hormone and Factor VIIa.
Leadership and Structure
Dr. Phillip Frost is the Chairman and CEO. The company has a standard corporate structure with departments focused on R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Rayaldee: A vitamin D prohormone used to treat secondary hyperparathyroidism in adults with chronic kidney disease. Market share is relatively small compared to larger pharmaceutical companies. Competitors include vitamin D supplements and other treatments for SHPT like calcimimetics (Sensipar by Amgen).
- BioReference Laboratories: Provides diagnostic testing services. Competitors include Quest Diagnostics (DGX) and Laboratory Corporation of America Holdings (LH).
Market Dynamics
Industry Overview
The healthcare industry is characterized by increasing demand for diagnostics, pharmaceuticals, and biologics due to aging populations and advances in medical technology.
Positioning
Opko Health Inc. operates in a competitive market with established players. Its competitive advantage lies in its diversified product portfolio and innovative technologies.
Total Addressable Market (TAM)
The global diagnostics, pharmaceuticals, and biologics market is estimated to be worth billions of dollars. Opko Health Inc. is positioned to capture a portion of this TAM through its products and services.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Innovative technologies
- Experienced leadership
- BioReference Laboratories strong market presence
Weaknesses
- High debt levels
- History of net losses
- Regulatory risks
- Dependence on key products
Opportunities
- Expanding market for diagnostics
- Growing demand for pharmaceuticals
- Strategic partnerships
- New product launches
Threats
- Competition from larger companies
- Pricing pressures
- Patent expirations
- Economic downturns
Competitors and Market Share
Key Competitors
- DGX
- LH
- AMGN
Competitive Landscape
Opko Health Inc. faces strong competition from larger, more established companies with greater resources.
Major Acquisitions
BioReference Laboratories
- Year: 2015
- Acquisition Price (USD millions): 1470
- Strategic Rationale: Expanded Opko's diagnostic testing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Growth has been uneven, driven by acquisitions and product development.
Future Projections: Analyst estimates vary, but project modest growth in revenue over the next few years.
Recent Initiatives: Focus on expanding diagnostic testing services and commercializing new pharmaceutical products.
Summary
Opko Health is a diversified healthcare company with exposure to diagnostics, pharmaceuticals and biologics, but with large debt and a history of net losses. BioReference Labratories provides a solid market presence. It faces strong competition and regulatory risk. It's future depends on successful commercialization of new products and effective debt management.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Opko Health Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 1995-11-02 | Chairman & CEO Dr. Phillip Frost M.D., Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2997 | Website https://www.opko.com |
Full time employees 2997 | Website https://www.opko.com | ||
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.